Headlines about Haemonetics Corporation (NYSE:HAE) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Haemonetics Corporation earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 46.6480605154888 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news articles that may have effected Accern’s scoring:

Shares of Haemonetics Corporation (NYSE HAE) opened at $47.12 on Friday. Haemonetics Corporation has a twelve month low of $33.09 and a twelve month high of $47.98. The company has a quick ratio of 1.72, a current ratio of 2.57 and a debt-to-equity ratio of 0.31. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of 28.89, a P/E/G ratio of 3.68 and a beta of 0.91.

Haemonetics Corporation (NYSE:HAE) last posted its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The company had revenue of $211.00 million for the quarter, compared to analyst estimates of $211.29 million. During the same quarter last year, the company earned $0.25 earnings per share. The company’s revenue for the quarter was up .5% on a year-over-year basis. equities analysts predict that Haemonetics Corporation will post 1.61 EPS for the current fiscal year.

A number of research analysts have recently commented on the stock. Zacks Investment Research cut shares of Haemonetics Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, August 29th. BidaskClub raised shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, August 8th. Morgan Stanley reissued an “equal weight” rating and set a $43.00 target price (up from $38.00) on shares of Haemonetics Corporation in a research report on Friday, October 6th. JMP Securities raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a research report on Thursday, July 13th. Finally, Barrington Research raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 target price on the stock in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. Haemonetics Corporation currently has a consensus rating of “Hold” and an average price target of $45.83.

COPYRIGHT VIOLATION WARNING: “Haemonetics Corporation (HAE) Earns Media Impact Score of 0.12” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/haemonetics-corporation-hae-earns-media-impact-score-of-0-12/1678057.html.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Insider Buying and Selling by Quarter for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.